Search filters

List of works by Jakub Klapaczyński

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection

scientific article published on 07 February 2020

Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis

scientific article published on 13 December 2019

Effectiveness and Safety of Pangenotypic Regimens in the Most Difficult to Treat Population of Genotype 3 HCV Infected Cirrhotics

scientific article

Factors influencing the failure of interferon-free therapy for chronic hepatitis C: Data from the Polish EpiTer-2 cohort study

scientific article published on 01 May 2021

Is an 8-week regimen of glecaprevir/pibrentasvir sufficient for all HCV infected patients in the real-world experience?

scientific article published on 10 November 2020

Low risk of HBV reactivation in a large European cohort of HCV/HBV coinfected patients treated with DAA

scientific article published on 13 June 2020

Pangenotypic and Genotype-Specific Antivirals in the Treatment of HCV Genotype 4 Infected Patients with HCV Monoinfection and HIV/HCV Coinfection

scientific article published on 13 January 2022

Real World Experience of Chronic Hepatitis C Retreatment with Genotype Specific Regimens in Nonresponders to Previous Interferon-Free Therapy

scientific article published on 03 March 2019

Real-world experience with Grazoprevir/Elbasvir in the treatment of previously "difficult to treat" patients infected with hepatitis C virus genotype 1 and 4.

scientific article